LAVA Therapeutics N.V. has entered into a clinical trial collaboration and supply agreement with Merck to evaluate its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in combination with LAVA-1207, a Gammabody designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cells, in metastatic castration-resistant prostate cancer (mCRPC).   Merck will provide pembrolizumab for the dose escalation and expansion phases of LAVA’s o...